NFKB1 and depressive symptom measurement: Inhibiting glucocorticoid release, NF-κB nuclear transcription, NLRP3 inflammasome activation and restoring microglial homeostasis in the hippocampus are novel strategies for the development of effective treatments for the management of depression in humans.